Given the incremental nature of orthopedic design improvements and the FDA’s low tolerance for risk, the value of generics lies in distribution, not in manufacturing. As reimbursement models change, squeezing out cost in distribution is rewarded. That’s the opinion of one generic device maker. Read the argument here.